News Sentiment

AXSM sentiment intelligence

Axsome Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 230.00 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-1.6% over one week, -8.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Axsome Therapeutics (NASDAQ:AXSM) Upgraded to "Strong-Buy" at BMO Capital Markets

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction -1.6% Price digesting
Trend fit Trend active -8.2% over four weeks
Fair value 100.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 7
MarketBeat 6
simplywall.st 5
Investing.com 3
Simply Wall Street 2
GlobeNewswire 2
TradingView 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 21
Analyst action 13
Deals and strategy 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
MarketBeat Direct company coverage

Axsome Therapeutics (NASDAQ:AXSM) Upgraded to "Strong-Buy" at BMO Capital Markets

BMO Capital Markets upgraded Axsome Therapeutics (NASDAQ:AXSM) to a "strong-buy" rating, contributing to a consensus "Moderate Buy" rating and an average price target of $261.48 among analysts. Despite the company missing Q1 earnings estimates, its revenue increased by 57.4% year

Tone
Positive 72/100
Event
Earnings
Published
22 Jul 2026 09:41
Source
MarketBeat
MarketBeat Direct company coverage

Axsome Therapeutics (NASDAQ:AXSM) Rating Lowered to Strong Sell at Zacks Research

Zacks Research has downgraded Axsome Therapeutics (NASDAQ:AXSM) from a "hold" to a "strong sell" rating. This comes despite a broader "Moderate Buy" consensus among analysts with a price target of $261.48. The company recently reported mixed quarterly results, with an EPS of -$1.

Tone
Negative 38/100
Event
Earnings
Published
22 Jul 2026 09:41
Source
MarketBeat
TipRanks Direct company coverage

Axsome Therapeutics Inc. (AXSM) Q3 2024 Earnings Report - Results, Call & Slides

Axsome Therapeutics Inc. (AXSM) has released its Q3 2024 earnings report, showing a beat on both EPS and revenue expectations. The company reported actual EPS of -$1.34 against a consensus of -$1.38, and actual revenue of $104.76 million compared to an expected $98.37 million, ma

Tone
Positive 70/100
Event
Earnings
Published
21 Jul 2026 17:41
Source
TipRanks
marketscreener.com Direct company coverage

BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target

BMO Capital has initiated coverage on Axsome Therapeutics with an Outperform rating and a price target of $310. This follows several recent positive developments for Axsome, including the FDA's acceptance of their New Drug Application for AXS-12 for narcolepsy treatment and the i

Tone
Positive 73/100
Event
Analyst action
Published
21 Jul 2026 11:12
Source
marketscreener.com
MarketBeat Direct company coverage

Fifth Third Bancorp Has $2.74 Million Stock Holdings in Axsome Therapeutics, Inc. $AXSM

Fifth Third Bancorp significantly increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 554.6% in Q1, now holding 16,214 shares valued at $2.74 million. Despite missing EPS estimates, Axsome Therapeutics' revenue grew by 57.4% year-over-year, and analysts maintain a "Modera

Tone
Positive 66/100
Event
Earnings
Published
21 Jul 2026 08:12
Source
MarketBeat
MarketBeat Direct company coverage

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Analysts

Axsome Therapeutics (NASDAQ:AXSM) has received a "Moderate Buy" consensus rating from 21 analysts, with an average 12-month price target of $259.05. Despite reporting quarterly revenue of $191.2 million, exceeding expectations and up 57.4% year-over-year, the company posted a lar

Tone
Neutral 50/100
Event
Analyst action
Published
19 Jul 2026 06:39
Source
MarketBeat
MarketBeat Direct company coverage

Axsome Therapeutics, Inc. $AXSM Stock Holdings Reduced by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 3.5% in the first quarter, though it still holds a significant position. Axsome Therapeutics reported mixed quarterly results, beating revenue expectations but missing on earnings per share.

Tone
Neutral 50/100
Event
Earnings
Published
18 Jul 2026 09:12
Source
MarketBeat
MSN Direct company coverage

Axsome gains as narcolepsy therapy undergoes FDA review

Axsome Therapeutics' stock rose after the FDA accepted its New Drug Application for solriamfetol for narcolepsy, setting a PDUFA date for February 12, 2026. The therapy has shown promise in improving wakefulness and reducing excessive daytime sleepiness in narcolepsy patients. Th

Tone
Positive 92/100
Event
Market update
Published
18 Jul 2026 08:12
Source
MSN
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)

Three analysts have issued bullish sentiments on several healthcare companies. Andrew Tsai from Jefferies maintained a Buy rating on Axsome Therapeutics with a $380.00 price target, while Ami Fadia from Needham maintained a Buy rating on Harmony Biosciences Holdings with a $45.00

Tone
Neutral 50/100
Event
Analyst action
Published
17 Jul 2026 15:12
Source
The Globe and Mail
Stock Traders Daily Direct company coverage

Responsive Playbooks and the AXSM Inflection

This article analyzes Axsome Therapeutics Inc. (NASDAQ: AXSM), highlighting weak near-term sentiment but strong long-term potential. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, and details m

Tone
Negative 40/100
Event
Market update
Published
17 Jul 2026 07:58
Source
Stock Traders Daily
Simply Wall Street Direct company coverage

Mental Health Stocks Gaining Fresh Attention After Eli Lilly’s Psychedelic Deal

Eli Lilly's recent deal involving AtaiBeckley has brought psychedelic and mental health treatments back into focus, prompting investors to re-evaluate companies in this sector. This article highlights three stocks – Axsome Therapeutics (AXSM), LifeStance Health Group (LFST), and

Tone
Positive 65/100
Event
Deals and strategy
Published
17 Jul 2026 01:39
Source
Simply Wall Street
AllSci Direct company coverage

Axsome's AXS-12 Advances to FDA Review for Cataplexy

The FDA has accepted Axsome Therapeutics' New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in patients with narcolepsy, setting a PDUFA target action date of May 1, 2027. AXS-12 aims to be a non-scheduled, orally dosed option for daytime use, distinct f

Tone
Positive 72/100
Event
Analyst action
Published
16 Jul 2026 17:39
Source
AllSci
Market source Direct company coverage

Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance

The FDA has accepted Axsome Therapeutics' New Drug Application (NDA) for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a decision expected by May 1, 2027. This potential approval could bolster Axsome's narcolepsy franchise, which already includes Sunosi. However, the

Tone
Neutral 50/100
Event
Regulatory and legal
Published
16 Jul 2026 15:39
Source
Market source
Sahm Direct company coverage

Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy Cataplexy

Axsome Therapeutics (AXSM) has received FDA acceptance for its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy patients, with a target decision date set and no advisory committee meeting planned. This regulatory milestone provides increased visibili

Tone
Positive 72/100
Event
Analyst action
Published
16 Jul 2026 03:41
Source
Sahm
GlobeNewswire Direct company coverage

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for treating cataplexy in narcolepsy. The FDA has set a PDUFA target action date of May 1, 2027, and does not currently plan an advisory committee meeting. AXS-12 has Or

Tone
Positive 71/100
Event
Analyst action
Published
16 Jul 2026 03:41
Source
GlobeNewswire
grafa.com Direct company coverage

Axsome FDA application accepted for 2027 target date

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy. This acceptance sets a formal target action date of May 1, 2027, for the drug, which is designed to address the sudden loss of muscle tone e

Tone
Neutral 50/100
Event
Analyst action
Published
15 Jul 2026 15:33
Source
grafa.com
Seeking Alpha Direct company coverage

Axsome gains FDA review for narcolepsy therapy (AXSM:NASDAQ)

Axsome Therapeutics' shares rose in premarket trading after the U.S. FDA accepted its marketing application for AXS-12 (reboxetine), an experimental therapy for narcolepsy. This marks a significant step for the neurology drug developer in bringing its treatment to market.

Tone
Positive 72/100
Event
Market update
Published
15 Jul 2026 11:48
Source
Seeking Alpha
Investing.com Direct company coverage

Axsome gets FDA filing acceptance for narcolepsy drug AXS-12

Axsome Therapeutics has announced that the FDA has accepted its New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy patients, setting a target action date of May 1, 2027. The drug, which has Orphan Drug Designation, targets the sudden muscle tone loss ex

Tone
Positive 70/100
Event
Analyst action
Published
15 Jul 2026 11:48
Source
Investing.com
Stock Titan Direct company coverage

FDA accepts Axsome Therapeutics (NASDAQ: AXSM) AXS-12 narcolepsy NDA

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027, and does not currently plan to

Tone
Positive 66/100
Event
Analyst action
Published
15 Jul 2026 11:16
Source
Stock Titan
TradingView Direct company coverage

Axsome Therapeutics NDA for AXS-12 accepted by FDA; PDUFA date May 1, 2027

The FDA has accepted Axsome Therapeutics' New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not currently plan to hold an advisory committee meeting for this application

Tone
Positive 68/100
Event
Analyst action
Published
15 Jul 2026 10:48
Source
TradingView
Quiver Quantitative Direct company coverage

Axsome Therapeutics Announces FDA Acceptance of NDA for AXS-12 in Narcolepsy Cataplexy; PDUFA Date Set for May 1, 2027

Axsome Therapeutics has announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not plan to hold an advisory committee meeting for this application. AXS

Tone
Neutral 50/100
Event
Analyst action
Published
15 Jul 2026 10:48
Source
Quiver Quantitative
GlobeNewswire Direct company coverage

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced it will report its second-quarter 2026 financial results on Monday, August 10, 2026, before the opening of the U.S. financial markets. Management will host a conference call at 8

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 14:40
Source
GlobeNewswire
Simply Wall Street Direct company coverage

Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?

Axsome Therapeutics has initiated a Phase 3 pediatric ADHD trial (FOCUS-2) for solriamfetol, expanding its strategy to broaden the drug's use across various CNS indications and age groups. This move, alongside an ongoing adolescent program, aims to diversify revenue but also inte

Tone
Positive 64/100
Event
Earnings
Published
14 Jul 2026 14:10
Source
Simply Wall Street
scanx.trade Direct company coverage

Axsome Therapeutics to report Q2 2026 results on August 10

Axsome Therapeutics will release its financial results for the second quarter of 2026 on Monday, August 10, 2026, before U.S. financial markets open. The company will also host a conference call at 8:00 a.m. ET to discuss these results and provide a business update. A live webcas

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 12:51
Source
scanx.trade
MarketBeat Direct company coverage

Hillsdale Investment Management Inc. Makes New Investment in Axsome Therapeutics, Inc. $AXSM

Hillsdale Investment Management Inc. initiated a new position in Axsome Therapeutics (NASDAQ:AXSM) by purchasing 53,363 shares valued at approximately $9.0 million. This comes as institutional and hedge fund ownership in Axsome Therapeutics remains high at 81.49%, with several ma

Tone
Positive 64/100
Event
Market update
Published
14 Jul 2026 11:43
Source
MarketBeat